Osteoporosis is defined as a condition of impairment in bone strength due to low bone mineral density and poor bone quality and predisposes Individuals to an increased risk of fractures. Osteoporosis may coexist with chronic kidney disease-mineral and bone disorder (CKD-MBD) and osteoporotic fractures occur in all stages of CKD. Management of osteoporosis in CKD should consider the pathophysiology of both disorders. Diagnosis and management of osteoporosis in patients With stages 1-3 CKD and patients without CKD are similar, but diagnosis and management decisions differ greatly once patients have stages 4-5 CKD. Discriminating between osteoporosis and CKD-MBD is best accomplished with quantitative bone hlstomorphometry. Biochemical markers, especially intact parathyroid hormone and bone-specific alkaline phosphatase, also may be helpful. When the diagnosis of osteoporosis is established, management in stages 4-5 CKO may include antiresorptive or anabolic agents, though evidence for efficacy is marginal in advanced CKD. Am J Kidney Dis. 64(2):290-304. © 2014 by the National Kidney Foundation, Inc.
INTRODUCTION
Osteoporosis is defined by a consensus conference of the National Institutes of Health (NIH) as a condition of impainnent in bone strength due to low BMD and po.or bone quality (see Box I for a glossary of key tenns). J Because bone quality cannot be measured in clinical practice, the operational definitions of osteoporosis are the occurrence of a lowtrauma (fragility) fracture in women or men 50 years or older after other causes of bone fragility have been excluded (eg, osteomalacia and osteogenesis imperfecta). 2 In 1994, a second diagnostic criteria for osteoporosis was established. A working group of the WHO published their criteria for the diagnosis of osteoporosis by BMD criteria in individuals who have not yet had a fragility fracture.
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Box 1. Glossary of Terms
• Bone-specific alkaline phosphatase (bone ALP): An osteoblast-derived bone formation marker: however. bonespecific alkaline phosphatase may be elevated in other diseases in which bone formation is not increased or normal (eg, osteomalacia, Paget disease, cancer in bone).
• Procollagsn type I amino-termlnal propsptids (PINP): A more specific osteoblast-derived bone formation marker.
• Renal osteodysirophy: A quaniitative histomorphometric classification of the bone diseases accompanying CKD.
• Chrcm/c kidney disease-miners/ and bone disorder (CKD-MBD): A term that embraces the systemic nature of the interactions between ttie metabolic bone diseases that accompany CKO linked to the pathophysiologlc processes of vascular/soft tissue calcification.
• Adynamic bone disease: A quantitative histomorphometricdelined bone disease characterized by absent or very low bone turnover.
• Bone turnover markers: Serum or plasma biochemical markers that reflect the systemic levels of bone turnover (fonnation/resorption).
• Mixed renal bone disease: A quantitative histomorphometric classification of bone histomorphometry in CKD:
mixArt nm<'!I h.nn,;1 l'.ii~AAS':1 is <1 ~oml'.linati,:in of <:lf:\fl:l~ts in bone mineralization with features of high bone turnover.
• Osteitls flbross cystica: A histologic feature of hyper· parathyroid bone disease characterized by increased bone resorptive cavities, increased osteoclast number, marrow fibrosis, and increased cortical porosity.
• Osteomalacla: A quantitative histomorphometric metabolic bone disease of diverse etiologies characterized by an increase in osteoid (matrix) surface (>80%), wide osteoid seams (>10 µm), and delay in mineralization lag lime (>100d).
• OStf!0porosis: A systemic metabolic bone disease of diverse causes characterized by impaired bone strength and increase In fragility fracture risk. The impairment in bone strength is due to a combination of reduced bone mineral density and altered bone quality. Clinically, osteoporosis can be diagnosed _ by the occurrence of a fragility fracture, or in patients without fracture, by the Wrirl(i Health Org1:1niz.ation dua! energy x-ray <1bsorp!i· ometry diagnosis (T score) of -2.5 or lower at the spine, femoral neck. total hip, or forearm.
• Parsthyroid hormone {PTH): The peptide hormone in the blood stream that regulates multiple end-organ functions. most importantly, se,um calcium concentration.
• Fibroblast growth factor 23 : A peptide that is secreted by osteocytes whose most Important biological function is regulation of serum phosphorus concentration by inducing phosphaturia. FGF-23 also has recognized functions to affect kidney production of 1,25 dihydroxyvitamin 0 synthesis, PTH production, vascular calcification, and bone turnover.
• Scferostin: A glycoprotein released by osteocytes that reg, ulates osteoblast activity and influences bone remodeling.
• Tartrate-resistant acid phosphatase (TRAP5b): An osteoclast cellular product that influences bone remodeling. TRAP5b serum or plasma concentration is a measure not of bone resorption as much as it is a measure of osteoclast number.
was to detennine the prevalence of osteoporosis in the world's population in order to ai~ in health-economic planning. Soon after 1994, the T score made its way into clinical use and also was included in the International Classification of Diseases, Ninth Revision as a second means of diagnosing osteoporosis in individuals who had not yet had a fragility fracture. The clinical utility of the T score lies in its use as a risk factor for osteoporotic fracture. Fracture risk approximately doubles for each standard deviation the B:MD is below -2.5 in untreated postmenopausal women compared to the same population of the same age with a T score of zero.
One limitation of the T score is that it does not define the cnuse of low BMD, and it should not be used as a stand-alone risk factor for making management decisions. 42 Second, measurable derangements in bone and mineral metabolism that suggest the presence of CKD-MBD, such as secondary hyperparathyroidism or hyperphosphatemia, are less pronounced at a GFR > 30 mlJ min unless there also are nonrenal-related causes of secondary hyperparathyroiclism 28 " 30 • 4345 (Box 3). Third, neither serum PTH nor serum phosphorus was systematically measured at randomization in the whole populations constituting the osteoporosis trials discussed. Compared to placebo, all the therapies approved for the treatment of postmenopausal osteoporosis have efficacy across the range of kidney function defined 1:>y the randomization criteria for each trial.
Thus, there seems to be an understanding in the metabolic bone community that the WHO criteria for the diagnosis of osteoporosis can be applied in a similar manner in patients with stages 1-3 CKD as long as there are no kidney-related biochemical abnormalities suggesting CKD-MBD. Likev.rise, there is agreement that given the same list of risk factors, FRAX can be applied to stages 1-3 CKD in a manner 5 However, more sensitive methodologies for measuring cortical bone of the radius or tibia, such as peripheral quantitative CT or high-resolution quantitative CT, perform better than 2-dimensional DEXA at discriminating between patients with and without fracture with stages 4-5 CKD (giving a receiver operating characteristic curve value of 0.78). 45 This greater differentiation may be related to the improved capacity of high~resolution 3-dimensional modalities to define bone size, bone microarchitecture, and cortical porosity compared to 2 dimensional (DEXA) measurements. High-resolution radiologic tools that are capable of quantifying bone microarchltecture are scientifically valid and very important for research into bone quality measurements. However, they are not clinically useful or reimbursable at this time, and data derived from quantitated CT have not been validated in the same way FRAX has been validated, using central DEXA. Routine quantitative CT of the spine or femur has shown risk prediction for osteoporotic fractures similar to central (spine and hip) DEXA. 16 . 4 5
Prospective studies need to be petfonned in large sample sizes of both sexes comparing 2-and 3-dimensional radiologic techniques, including the hip-derived quantitative CT bone strength analysis, finite-element analysis, and vertebral-derived trabecular bone score 15 • 16 across a spectrum of CKD in order for there to be widespread application of 3-dimensional bone architecture measurement techniques in clinical practice.
Implications for Case
The 54-year-old man with ESRD presented in the c!inical c~se introduced previously has osteopu1usis, both as defined by WHO criteria and by the occurrence of a low-trauma hip fracture. As discussed in the previous sections, the 2 clinical criteria for the diagnosis of osteoporosis cannot be applied to stage 5
CKD. The diagnosis of osteoporosis in stages 4-5
CKD at the present time can only be an exclusionary one by excluding the other fonns of renal bone disease that also may accompany CKD. Currel)tly, this exclusion can be accomplished in 2 ways: by profiling biochemical markers of bone turnover or by double tetracycline-labeled quantitative bone histomorphometry (eg, transUiac bone biopsy).
BIOCHEMICAL MARKERS OF BONE TURNOVER
The human body remodels (turns over) bone at both cortical and cancellous sites. Bone remodeling is regulated by both systemic factors (eg, PTH, phosphorus, 1,25-dihydroxyvitamin D, circulating sclerostin, and perhaps FGF-23), as well as by local bone microenviroment factors (RAN.KL [receptor-activated nuclear factor-KB ligand), osteoprotogerin, sclerostin, insulin growth factors, and ephrin-B2/ephrin-B4). 50 • 57 One major purpose of remodeling is to repair the microdamage that occurs in the skeleton with daily mechanical stress on bone. In clinical practice, there are a number of biochemical markers of bone turnover that can be measured in serum. Two markers that are not cleared by the kidney are the resorption marker (or more accurately, the osteoclast cellular number marker) tartrate-resistant acid phosphatase (TRAP5b; encoded by the ACP5 gene) and the formation marker (or more accurately, the osteoblast activity marker) bone-specific ALP. For the osteoblast-derived marker PINP, there are 2 types of assays: one that measures the total (monomer and trimer) form of PINP (Roche Diagnostics) and one that measures only the intact trimeric form of PJNP (IDS-iSYS Intact PINP chemiluminescent immunoassay [Immunodiagnostic Systems] and Orion Uni-Q PINP radioimmunoassay, available through Immunodiagnostic Systems). The trimer is not cleared by the kidney, whereas the monomer is cleared by the kidney. Currently, th~re are insufficient data to determine whether the difference in clearance between the 2 fonns of PINP is enough to influence clinical use of the intact PINP in detennining 71 In this study, a large sample size of quantitative bone histomorphometry was analyzed along witli the assays for tissue-specific ALP and serum PTH. The authors concluded that serum PTH level < 150 pg/ mL (and even more so, <JOO pg/mL) in dialysis patients not receiving therapies to lower serum PTII .levels had a high positive predictive value for renal adynamic bone disease. Likewise. adynamic bone disease was suggested by a tissue-specific ALP level in the lower quartile of the laboratory reference range. At the other end of the spectrum, a high ( 6 times above the upper limit of the reference range) serum PTH level had a high positive predictive value for hyp.erparathyroid bone disease (osteitis fihrisa cyctica), as did a high level of bone ALP. However, it should be kept in mind that a high bone ALP concentration also may be seen in a number of metabolic bone diseases that are not hyperparathyroid bone disease and can coexist in patients with stage 5 CKD, such as Paget disease or metastatic cancer of bone (Box 5). In the management of patients with stages 4-5 CKD and low T scores or fractures, adynamic bone disease probably is the most important disease to . · exclude, and here, the lower PTH and bqne ALP levels may have discriminatory value. Discrimination between adynamic bone disease and osteoporosis is most important in the context of management of the patient with fracture with stages 4-5 CKD because in theory, the antiresorptive agents used to treat osteoporosis would lower bone turnover when bone turnover is low to begin with. and is on peritoneal dialysis therapy, also linked to low bone turnover. 75 Because his biochemical profiling and clinical conditions were both suggestive of adynamic bone disease, the gold standard for discrimination among the heterogeneous fonns of renal bone disease was perfonned: quantitative bone histomorphometry. parathyroid bone parameters have a .spectrum of histomorphometry according to the severity and longevity of the hyperparathyroid disorder, osteomalacia has a clear set of criteria required for its definition, and adynarnic bone disease generally is considered to be a turnover disorder best defined by the absence of any single or double tetracycline labels (Fig 1) .
BONE BIOPSY FOR QUANTITATIVE PURPOSES
37
Though bone biopsy is definitive in the diagnosis of ostoo.mafa.cia, the disease aisu always hais a bioch~rnicai 
Implications for Case
Our patient had levels of bone turnover markers that
were not discriminatory enough to distinguish the cause of bone turnover, so a transiliac biopsy was perfonned and adynamic renal bone Jist:ast: was diagnosed. Therefore, both the low T score and large fragility fracture were due in part to adynamic bone disease. The NIH definition of osteoporosis encompasses bone quality components associated with microarchitectural changes in bone, and in that regard, a component of our patient's impairment in bone strength might be due to osteoporosis as defined by the NIB. Adynamic bone disease is an important disorder to diagnose because there may be modifiable risk factors associated with it. In addjtion, treatment of osteoporosis in the presence of adynamic renal bone disease may allow for consideration of off-label use of an anabolic agent instead of an antiresorptive agent due to the pre-existence of absent bone turnover to begin with. Based on our patient's biopsy-proven adynarnic bone disease of unknown cause ("idiopathic"), he received teriparatide off label. Use of this agent for adynamic bone disease is not evidence based, but may be considered in very high-risk patients with proven adynamic bone disease because it is the only FDAapproved agent at this time that has putative mechanism(s) of action to stimulate bone formation, including the inhibition of sclerostin binding to the
osreooiasr. · · J:Secause osteocyte-aenved sclerostin 
TREATMENT OF OSTEOPOROSIS IN STAGES 4-5 CKD
Treatment of osteoporosis is an important consideration for patients who have experienced a fragility 296 Paul D. Mmer fracture, due to the high mortality and morbidity associated with osteoporotic fractures, and even more so in the CKD population. PopuJation data have confinned the short-and long-tenn mortality associated with all fractures, inclu.ding vertebral fractures, in both sexes. 110 Thjs mortality is even greater in patients with CKD, probably associated with the overall greater mortality from all causes in severe CKD.
The main limitation of the FDA-approved pharmacological choices for osteoporosis is the .lack of evidence for fracture risk reduction in patients with severe (stages 4-5) CKD, with the exception of a few post hoc analyses in smaller sample sizes of the trial cohorts for postmenopausal osteoporosis. Titls review focuses on the most widely used treatments: the antiresorptive agents (bisphosphonates and denosumab) and the only available anabolic agent, teriparatide.
Antiresorptive Agents
Antiresorptive agents are a class of agents that have a common pathway·resulting in the inhibition of bone resmption. 81 FDA-approved antiresorptive agents include calcitonin, estrogens, selective estrogen receptor modulators, bisphosphonates, and denosumab. Each antiresorptive agent has its OV.'Il unique mechanism of action. Because bisphosphonates and densoumab are the most widely used antiresorptive agents for osteoporosis, they are focused on in this review.
Bisphosphonates are biological analogues of naturally occurring pyrophosphates, which in turn are degradation products of adenosine triphosphate metabolism. Pyrophosphates are metabolized rapidly by the ubiquitous presence of pyrophosphatases, whereas bisphosphonates are not metabolized. When they enter the blood stream, bisphosphonates are taken up rapidJy by bone, the only tissue that binds bisphosphonates due to the physiochemical attacbment. 82·r,3 In bone, bisphosphonates inhibit bone resorption in 2 ways: by the physiochemical process of stabilizing the calcium-phosphorus surface and by the cellular process of inhibiting osteoclast activity (Fig 2) . 112 Bisphosphonates are cleared by the kidney by both filtration and active proximal tubular secretion.42·84·85 They are l'etained in bone in the remodeling resorption cavity and the amount of bisphosphonate retained probably is a function of the baseline remodeling space, the long-tenn rate of bone turnover, and GFR. Although oral bisphosphonates are poorly absorbed (<I% of a single dose) and 50% of that is excreted by the kidney, intravenous bisphosphonate shows 100% bioavailability (again, with 50% of the intravenous dose excreted by the kidney). Oral bisphosphonates have never been shown to have kidney toxicity, whereas intravenous bisphosphonates, especially Abbreviations: ALP, alkaline phosphatase: CKD, chronic kidney disease; eGFR, estimated glomerular fiitration rate; IV, intravenous; PTH, parathyroid horme; RANKL, receptor-activated nuclear factor-KB ligand; SC, subcutaneous.
8 O1I-label use of IV bisphosphonates in patients with stages 4-5/5D CKO with osteoporosis and prevalent fractures: no dose adjustments; low infusion rate down to minutes. zoledronic acid, may acutely reduce GFR bl a tubular lesion that mimics acute tubular necrosis.
8 ' Although intravenous ibandronate, the only other intravenous bisphosphonate approved for osteoporosis, has not been shown in either clinical trials or postmarketing reports to have a negative effect on the kidney, there have never been head-to-head studies comparing effects on the kidney of these 2 bisphosphonates in healthy individuals or those with decreased GFR.
42
• 87
Even zoledronic acid, when administered slower than the 15 minutes recommended by the product label, seems safe in clinical experience in patients with decreased GFR. Data from the zoledronic acid cancer trials suggest that the potential kidney do.mo.ge tho.t
Am J Kidney Dis. 2014;64 (2):290-304
can be observed with zoledronic acid may be related to dose and rate of infusion.
'
89 Zoledronic acid given as a dose of 8 mg monthly versus 4 mg monthly and given over 5 minutes versus 15 minutes induced a large proportion of acute kidney failure not seen with the lower dose and slower infusion rate. These data would suggest that from a pharmacokinetic profile, the kidney damage might be related to the peak concentration of the drug, rather than to the area under the curve. Nevertheless, because 50% of absorbed bisphosphonates are cleared by the kidney and . because of the lack of clinical trial data in patients with GFRs < 30 mUmin, bisphosphonates carry 
• 91
The initial clinical trials developed for the FDA approval process did not require or measure eGFR or GFR as inclusion/exclusion criteria in any preplanned design. but only serum creatinine concentration. It took the osteoporosis community longer than the nephrology community to realize that a serum creatinine concentration may fall within a nonnal laboratory reference range. Y,et a patient with low body mass index may still have a significant reduction in GFR. Only the FDA approval studies for zoledronic acid and densoumab used eGFR as randomization criteria.
Bisphosphonates as a class should be administered for 3-5 years and then discontinued in lower risk patients, which sometimes is referred to as a bisphosphonate drug holiday. The FDA advises this strategy based on the lack of efficacy of bisphosphonates on fracture risk reduction beyond 5 years, as well as the appearance of bisphosphonate-associated atypical femur fractUies with long duration of use, especially beyond 5 years. 92 Although these atypical fractures are rare. they have a large morbidity. In addition, the risk for these atypical subtrochanteric 298 femur fractures decreases by at least 70% within the first year of bisphosphonate discontinuation, although the pharmacology of bi~hosphonates indicates they are still being recycled.
3 The biological answer to why risk declines despite continual reduction in bone turnover is not known, but it is important for physicians to be aware that even though risk declines, it does not disappear. fu that regard, patients should be made aware of a prodrome symptom that may precede the fracture displacement weeks before the break: a deep anterior thigh or groin pain that does not go away with rest OJ' . a supine position. fu these cases, xray of the femoral shaft may reveal the classic stress fracture and periosteal reaction. fu high-risk patients (those with femoral neck T scores -2.5 or lower) who have been on bisphosphonate therapy for 3-5 years, the FLEX (Fosamax [alendronate] Long-tenn Extension) trial suggests that the benefit of continuation seems to far outweigh the risks. 94 Recent publications on the bisphosphonate benefit to risk ratio provide helpful reviews of the large benefit that bisphosphonates may provide in postmenopausal osteoporosis when used in the right population for the right duration. 95·96 For patients at high risk who have discontinued bisphosphonate therapy, the FDA advises switching to a different approved osteoporosis therapy with a different mechanism of action. Although there are no data for duration of bisphosphonate use in more advanced CKD. it seems logical that because bone retention may be greater in CKD, duration of use ideally would be shorter than 3-5 years. Finally, there is a growing amount of retrospective cohort data suggesting that bisphosphonates may be associated with a reduction in all-cause mortality, including cardiovascular mortality. 97 If there is such a link, the ~echanism is unknown, though bisphosphonates have been shown to alter cellular pathways in vascular endothelial cells that influence vascular calcification. 98 • 100 These data are relevant to the issue of bone turnover and vascular calcification in CKD. Because there may be a link between low bone turnover and greater risk for vascular calcification in severe CKD, 101 phannacological lowering of bone turnover should be done in this population only if very. low ( eg, adynamic) bone disease has been excluded. Denosumab is a fully human monoclonal antibody that binds to the osteob}ast-(and osteocyte)-derived glycoprotein RANKL. inhibiting· it from binding to the osteoclast membrane receptor RANK and thereby inhibiting osteoclastogenesis. 
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osteoclasts on biopsy. JU,j Denosumab clinical trial data show complete reversibility of both bone turnover markers and BMD effect 6 months after administration of the 60-mg dose and a return to responsiveness with repeat administration (Fig 3) . ios The registration trials show strong evidence for fracture 1isk reduction in postmenopausal osteoporosis of all fractures (hip, nonvertebral, and vertebral) with the registered dose of denosumab (60 mg subcutaneously every 6 m onths). 106 In the extension trials of denosumab that have now been reported out throu?ih 8 years, there is a continual increase in BMD.
• 1 ) 8
Because denosumab is metabolized (in the reticuIoendothelial system) and the biological effect wanes after 6 months, it seems, but is not established to date, that denosumab treatment must be continued indefinitely to have a benefit. One of the fundamental limitations of all osteoporosis clinical trials is that the placebo anns cannot be continued indefinitely, especially in high-risk patients, so that after 3-5 years in most trials, the continual fracture benefit is always compared to the reduction in fracture risk seen with the original randomly assigned population ..
From a safety standpoint, denosumab seems to be safe with long-term exposure. In the original clinical trial, the only significantly different safety signal in the treated group as opposed to the placebo rum were reports of skin "cellulitis," most of which cleared with topical or antibiotic therapy .
108 Nevertheless, because deitosumab is a biologic and the RANKL-RANK system is ubiquitous throughout the body, general immune suppression must be a safety consideration, especially in patients with immune suppression, including patients treated by other biologics and those who are posttransplantation. There is a paucity of data in these groups.
In addition, it has been observed that in hemodialysis patients, denosumab m:ay induce significant hypocalcemia. i n 9 This hypocalcemic effect may be mitigated by ensuring adequate 25-hydroxyvitamin D levels and calcium intake.
In addition, for the population with kidney disease, there are additional considerations related to denosumab use. On quantitative bone histomorphometry in the original registration trials, there were significantly more patients who had no single tetracycline labels in the treated as opposed to the placebo groups.
104
Although absent single tetracycline labels may be seen in <5% of healthy individuals, the preponderance of absent labels with denosumab treatment suggests the absence in a subset of the clinical trial patients of bone min~ralizotion during the drug administration. Though levels of bone turnover markers rebound to even greater than baseline within 6 months after discontinuation of denosumab therapy, it is unknown whether mineralization returned in the original registration cohort. In a separate nonregistration study, ST AND (the Study ofTransitioning From Alendronate to Denosumab ), double labels were seen in patients exposed to denosumab after its discontinuation. 1011 However, it is unknown whether these patients had absent labels at baseline. The point is that if However, the issues of efficacy versus safety in these populations are separate considerations. Finally, because vascular calcification is .the major factor associated with death in the CKD population, a discussion of the data for vascular calcification in the denosumab trials is warranted. This is important because serum osteoprotogerin levels increase with denoswnab administration as a regulatory response when RANK pathways are inhibited. There are conflicting and opposing data with regard to the influence of osteoprotogerin on vascular calcification.
111
• 112 In the densoumab registration trial, vascular calcification was assessed by lateral lumbar spine x-rays done in order to assess for incident vertebral compression fractures. Data recently published suggest (hat vascular calcification scores did not change between the treated versus the placebo groups over the 3-year duration of the trial.
113 Larger prospective trials are being designed to examine the relationship betw·een densoumab use and vascular calcification, using a variety of more sensitive means to measure vascular calcification.
Anabolic Agents
The only anabolic agent FDA approved for the treatment of osteoporosis in women and men, as well as for the treatment of glucocorticoid-induced osteoporosfs, is a recombinant protein encompassing the first 34 amino acids of human PTH (teripara~ tide).' 14 · 117 Teriparatide stimulates the fonnation of new bone by other ceJlular and regulatory pathways. 118 The initial trial completed for FDA approval for posnnenopausal osteoporosis lasted 18 months, 16 months shorter than the FDA refl,uires for the approval of treatments for osteoporosis.
1 1 The teriparatide trial was cut short in part due to the appearance of osteogenic sarcoma in the Fischer strain of rat, an animal model that predominately models rather than remodels bone. After many FDA advisory board hearings, the FDA concluded that this specific tumor is a rat-specific issue and wanted the sponsor (Eli Lilly and Co) to restart the trial, but many of the participants, now 6 months off the trial, had been started on other approved osteoporosis therapies. Hence, the 300
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FDA granted approval based on 18-month data, due in part to their own decision to temporarily halt the trial and in part to the significant reduction in vertebral and nonvertebral fracture incidence seen in the registration trial by the 18th month. The teriparatide registration trial, like other registration trials for osteoporosis, did not randomly assign participants with known stages 4-5 CKD. However, like the previously mentioned post hoc analysis for alendronate, risedronate, and denosumab that had subsets of the randomly assigned population with eGFRs as low as 15 ml/min, the teriparatide trials had small subsets with eGFRs as low as 30 mL/ min. 120 In these subsets, there were similar increases in BMD and PINP values across tertiles of eGFR. Fracture numbers were too small to have power for statistical analysis across these 3. tertiles. There were no changes in kidney function as assessed by changes in serum creatinine or serum calcium concentrations as a function of eGFR during the registration trial with the approved 20-µg/d or the higher 40-µg/d doses of teriparatide. Although 24-hour urine calcium excretion increased on average -50 mg/d greater than in the placebo group, there was no greater risk of clinical nephrolithiasis, though pre-existing kidney stones were an exclusionary criterion for trial randomization. Serum uric acid levels increased significantly more than in the placebo group, though the clinical consequences of this change in serum uric acid levels over the trial duration are unknown.
There are no data for the effect of teriparatide in individuals with stages 4-5 CKD 01· in individuals with bone biopsy-proven adynamic renal bone disease. The use of teriparatide in stages 4-5 CKD is off label and its use in known adynamic bone disease is predicated only on the knowledge that an anabolic agent can increase bone turnover and improve bone microarchitecture, shows a strong con-elation with increases in BMD and fracture risk reduction, and is a disease for which there are no known therapies.
-124
Hence, it is possible, though unproved, that teriparatide may have a beneficial role in idiopathic renal adynamic bone disease. It also is unlmown whether teriparatide will have the same anabolic effect in patients with pre-existing secondary hyperparathyroidism. Baseline PTH levels were measured in only a small subset of the teriparatide postmenopausat osteoporosis registration trials and were nonnal. Hence, it is unknown whether sustained and uncorrected elevated PTH levels could mitigate the anabolic effect of teriparatide.
Implications for Case
Our patient, with biopsy-proven idiopathic renal adynamic bone disease, was administered teriparatide, 20 µg/d. Although there have been no additional fractures over the 2-year period, his PINP level increased 60 µg/L from baseline and his bone ALP level doubled from baseline 4 months after teriparatide therapy initiation, suggesting an anabolic response. In the postmenopausal osteoporosis registration trials for teriparatide, lumbar spine BMD returned to baseline 12 months after discontinuation of teriparatide therapy unless the patients were using a bisphosphonate, though there seemed to be maintenance in fracture risk reduction. 125 Our patient was started on treatment with 
